HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1, citing regulatory...
HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, reported financial and operational results for the fourth quarter and...
HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial...
HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms....
Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk ...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing advanced cardiac insights, announced that its management team will attend several investor and...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the enrollment of the first patients in its ALIGN-ACS...
HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings ALIGN-ACS study expected to complete...